Session Abstract – PMWC 2023 Silicon Valley

Showcase Track S2 - January 25 9.00 A.M.-1.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-1.15 P.M.,Showcase Track S1 - January 27 11.15 A.M.-1.15 P.M.


The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

  • Clinical Dx/Oncology (including Liquid Biopsy)
  • Clinical Dx/Cardio Vascular
  • Clinical Dx/Nerodegenerative


Confirmed Presenting Companies:

 Speaker Profile

Ph.D., CTO, Dxcover Ltd

Biography
Dr Baker is the inventor of the Dxcover Liquid Biopsy suite and is responsible for the technical and scientific strategy and direction of the company. He was awarded a prestigious fellowship straight after PhD to work at the Robert Koch Institute and Harvard Medical School. He followed this with periods at the Ministry of Defence and several academic institutions. He is a global leader in clinical spectroscopy who has been awarded Top 6 Best British Tech Pioneers (2020), Fellow of the Society of Applied Spectroscopy (2020), Top 40 under 40 analytical scientists (2018), RSC Harrison Meldola Memorial Prize (2017) and the Emerging Leader in Molecular Spectroscopy (2016) amongst others. He is committed to the translation of his inventions from the bench to the bedside for the benefit of patients and global health.


Clinical Dx Showcase:
Dxcover Ltd

A clinical stage medtech company whose aim is to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other disease to improve survival and quality of life

Spectroscopic Liquid Biopsy for Multi-Cancer Early Detection
We present a rapid, low cost spectroscopic liquid biopsy platform capable of detecting cancer early

 Speaker Profile

Ph.D., Associate Director Translational Research, Epic Sciences

Biography
Dr. Giuseppe Di Caro has over 12 years of leading the design and execution of translational research studies in oncology. He is currently Associate Director of Translational Research for Epic Sciences, acting as a scientific subject matter expert for oncology biomarkers in the breast and lung cancer therapeutic area and clinical development lead in liaison with academic KOLs and biopharma partners. Before that, he was a Research Project Leader (RPL) at Pfizer advancing immune-oncology large molecule programs. He led a large cross-functional team from discovery and Lead optimization to candidate selection and development. His academic tenure included a Ph.D. in Experimental Pathology at the University of Milan and a Postdoctoral fellowship at the University of California San Diego, Department of Pharmacology. He led several peer-reviewed scientific articles aimed to improve the classification of tumor heterogeneity in large datasets of cancer patients and demonstrated the role of various tumor-infiltrating immune cells as predictive biomarkers.


Clinical Dx Showcase:
Epic Sciences

 Speaker Profile

PHD, Director of Digital Health, Astellas Pharma

Biography
Dr. Jin Lee is the Director of Digital Health at Astellas pharma. She most recently was the CEO and founder of BabyNoggin, a maternal/child app platform screening for postpartum depression and child’s development issues and help those connect to additional care as needed. She was formerly at the innovation centers and venture arms of Humana, 4th largest health insurance company, and Providence St. Joseph Health, 3rd largest nonprofit hospital system, focused on series A & B digital health investments. Based in San Francisco, Dr. Lee advises multiple digital health startups and accelerator programs.


Clinical Dx Showcase:
Astellas Pharma

Astellas has strived to continue to create innovation and deliver innovative medical solutions that meet the needs of patients. Looking forward, we are committed to achieving our VISION of turning innovative science into VALUE for patients.

Platform for Menopausal Women
Astellas incubator is developing a platform to help menopausal women learn about and manage their symptoms.

 Speaker Profile

Senior Field Application Scientist, Twist Bioscience

Biography
As an Application Scientist at Twist Bioscience, Casey focuses on custom NGS project support, new product development, and training. He has ten years of in-depth industry experience in qPCR, Sanger sequencer, and NGS.


Clinical Dx Showcase:
Twist Bioscience

Twist Bioscience, a rapidly growing synthetic biology company, is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Leading the way in Target Enrichment Technology
Learn how Twist Bioscience is writing the future of cancer research with early cancer detection offerings.

 Speaker Profile

MBA, Chief Commercial Officer, OncoHost

Biography
Chris Dingman has over 24 years of experience in the healthcare industry. A top-performing, proven sales leader with extensive expertise in oncology molecular diagnostics and the pharmaceutical industries, Chris has a successful track record of developing and launching laboratory-developed tests by growing commercial and marketing capabilities. He has helped build top-tier, successful sales teams with a culture of putting patients and physicians first. Chris holds a BA in marketing (cum laude) from the University of Colorado, Boulder, and an MBA in global management.


Clinical Dx Showcase:
OncoHost

OncoHost has developed the PROphet® platform, a plasma-based, proprietary proteomic analysis tool that guides decision-making in the choice of first-line treatment in cancer patients, analyzes resistance mechanisms, and suggests potential treatment combinations to overcome this resistance.

A Proteomics Platform for Cancer Disease Management
The next-generation precision oncology solution: a real-time, personalized, and dynamic disease navigator.

 Speaker Profile

Ph.D., Chief Scientific Officer, Nucleix

Biography
Dr. Catherine Schnabel brings over 20 years of scientific and leadership experience in the biomedical and molecular diagnostics industries. Prior to joining Nucleix, Cathy was the Chief Scientific Officer of Biotheranostics, where she led the development and translation of proprietary molecular signatures for breast cancer and metastatic disease, including incorporation of these novel technologies into clinical practice guidelines. An industry leader in evidence-based diagnostics, she has authored over 100 peer-reviewed publications and disclosures and is an inventor on several patents. Cathy previously held research positions at Genentech, Genoptix and Amylin Pharmaceuticals, where she investigated and launched first-in-class therapies and biomarkers. Cathy holds a Ph.D. in cell and developmental biology from the Center for Advanced Biotechnology and Medicine at Rutgers University and was a fellow of the NIH and the Leukemia and Lymphoma Society at Stanford University.


Clinical Dx Showcase:
Nucleix

Nucleix is a liquid biopsy company revolutionizing early cancer detection and recurrence monitoring through its pioneering methylation based EpiCheck technology. Construction of its NGS Lung Cancer Atlas focused on stage I disease will provide a high-resolution platform to discover novel, multi-omic biomarkers for cancer screening.

EpiCheck®, cancer detection at the earliest moment
Advancing liquid biopsy tests to detect cancer earlier for better outcomes for patients.

 Speaker Profile

M.D., MD, MPH, M.D., M.P.H., FACP, Chief Scientific Officer, InterVenn Bioscience

Biography
Klaus Lindpaintner, MD, MPH, FACP, CSO at InterVenn Biosciences, previously held senior positions at Pfizer as Sr. VP of Human Genetics and Computational Biomedicine, at Roche, as Head, Roche Center for Medical Genomics, spearheading the company’s efforts in personalized health care; as CSO at Thermo-Fisher-Scientific; and on the faculty of Harvard Medical School. Klaus has co-authored some 250 scientific papers, and holds honorary and adjunct professorships at several academic institutions. He serves on numerous boards, working groups, and advisory panels for trade organizations, regulatory authorities, and non-governmental organizations on issues related to the successful implementation and leverage of novel technologies in health care. Klaus graduated from Innsbruck University Medical School and from Harvard School of Public Health. He pursued post-graduate training and specialization in internal medicine, cardiology, and clinical and molecular genetics in the US and Germany and is a Diplomate of the Boards in these specialties.

Talk
Glycoproteomics: Next Generation Biomarkers in Personalized Health Care
Recent advances in analytical technology, based on a combination of massspectrometry and artificial intelligence, have opened up a vast new territory of powerful biomarkers, orders of magnitude richer and more sensitive and specific than genomics and proteomics: posttranslational modification moieties of proteins, specifically glycosylation isoforms, as demonstrated by InterVenns data across a range of indications.


 Speaker Profile

Ph.D., CEO and Co-founder, ImpriMed

Biography
Sungwon Lim is a bioengineer/entrepreneur with 20 years of collective experience in academia, pharmaceutical companies, and biotech industries. He co-founded ImpriMed in 2017 with a strong motivation to innovate a way to help cancer patients who need an effective treatment ‘today, by optimizing and personalizing drug treatment options currently available in our medical toolbox. ImpriMed builds a comparative oncology platform for precision medicine. The team first develops and validates new cell-based, functional precision medicine technologies and AI-based predictive models in the veterinary oncology space at a significantly higher speed with readily accessible clinical data. Then the collected database and knowledge are applied to human oncology for the same cancer type. Dr. Lim received his Ph.D. in Bioengineering from Stanford University, M.S. in Translational Medicine at U.C. Berkeley and U.C. San Francisco, and B.S. in Chemical and Biomolecular Engineering at Korea Advanced Institute of Science and Technology.


Clinical Dx Showcase:
ImpriMed

ImpriMed provides an anticancer drug efficacy prediction service using artificial intelligence on a patient's live cancer cell data, aiming to help oncologists personalize a treatment regimen tailored to each patient's unique cancer in both human and veterinary oncology.

Reinventing precision medicine: from dogs to humans
ImpriMed’s comparative oncology platform enables new precision medicine services for both human and animal cancers.

 Speaker Profile

Ph.D., Vice President, Scientific Consultant, Pierian

Biography
Dr. Bredemeyer is a product leader at Pierian, creating valuable solutions for clinical genomic laboratories through the development and growth of Pierian’s LDT and IVD platforms. In collaboration with Pierian’s Knowledgebase and software teams, he has helped design an automated tertiary analysis and clinical interpretation system and partnered with biocurators to create curation processes and automation for medical device compliance. He previously led Pierian’s Customer Success team and worked with numerous customers to bring workflow and reporting solutions to clinical molecular laboratories. Dr. Bredemeyer holds a Ph.D. in Immunology from Washington University in St. Louis. He served in policy and finance roles at the NIH and at Massachusetts General Hospital research labs. Dr. Bredemeyer helped lead NGS-based clinical assay development and validation efforts at Washington University’s Genomics and Pathology Services laboratory, an early pioneer in clinical NGS testing.


Clinical Dx Showcase:
Pierian

Pierian is a partner in precision medicine, enabling clinicians and medical facilities to advance clinical genomics programs and modernize patient care.

Democratizing Clinical ’Omics Globally
Precision medicine will reach patients worldwide when physicians and laboratories form partnerships.

 Speaker Profile

CEO, Quantum Insights Inc.

Biography
Bernard Chen trained in traditional statistics before managing product and analytics teams for companies like Apple, Ubisoft, and Scopely that could generate 100k samples of user data in days. Oncological data is more complicated to acquire and more complicated in its interactions, but the underlying problems for anyone working with data remain the same: 1) Have I asked my questions correctly? 2) Do I have the right data to answer my questions? He co-founded Quantum Insights with Stanford physicist, Marvin Weinstein, in 2017 to apply a quantum mechanics-based algorithm to big data. QI’s algorithm isn’t better than other algorithms - it’s different. That difference frequently identifies un-predicted associations that can be used to classify patients or sub-type diseases for our partners in pharma.


Clinical Dx Showcase:
Quantum Insights Inc.

Quantum Insights uses principles from quantum mechanics to identify diagnostic signatures and improve patient outcomes.

Finding Off-Label Treatments for Rare Diseases
Kidney renal papillary cell carcinoma (KIRP) has no FDA-approved treatment. By clustering cancers in the TCGA, we were able to identify the 5 most-similar cancers. Three drugs were identified that targeted genes which were significant in our classification of KIRP.

 Speaker Profile

Chief Business Officer, ChromaCode

Biography
Padma has 15+ years of experience leading and transforming organizations with disruptive diagnostic technologies to revenue stage companies with market leading tests. She has successfully launched multiple diagnostics globally, as kits and CLIA services, driving test inclusion as standard-of-care with expertise in oncology and transplant monitoring markets. Prior to joining ChromaCode, Padma held key leadership roles at Affymetrix, Roche, Guardant Health, CellMax Life, and Oncocyte.


Clinical Dx Showcase:
ChromaCode

ChromaCode’s HDPCR technology enables any laboratory in the world the ability to offer high-value diagnostics for Oncology Dx, MRD, Blood-based Monitoring, NIPT, and Infectious Disease.

HDPCR: Empowering High-Value Diagnostics for All Labs
Empowering high-value diagnostics for all labs in Oncology, MRD, Blood-based Monitoring, NIPT, and Infectious Disease.

 Speaker Profile

BEng, MSc., CEO, ARC Regulatory

Biography
Seamus Kearney graduated from the Queens University of Belfast with an MSc in Engineering and immediately began his career in the medical devices industry, where he has spent the last 22 years in a variety of roles from development lead, project management, QA/RA and clinical operations. Seamus has worked with many of the global leaders in the in vitro diagnostics industry, including J&J, Roche Diagnostics and QIAGEN and founded ARC Regulatory in 2010 with the aim of supporting companies in the IVD sector through myriad global regulations for device development and clinical validation. Over the past 7 years, ARC has focused on the precision medicine sector, supporting pharma and their Dx partners in global compliance from vendor selection, due diligence, Dx regulations, GCP, study management and monitoring.


Clinical Dx Showcase:
ARC Regulatory

ARC Regulatory is a niche provider of global regulatory and clinical research solutions to the precision medicine and IVD industry. Our mission is to support companies, from the world’s top pharmaceutical and biotech leaders to medical start-ups with the ambition to improve patient care.

How IVDR is Impacting Precision Medicine Trials
With IVDR Date of Application already taken place, ARC plans to deliver a talk surrounding current regulations.

 Speaker Profile

Chief Executive Officer, Exai Bio Inc

Biography
Pat brings more than 20 years of leadership experience as a healthcare entrepreneur to his role as co-founder and CEO of Exai. He previously served as an Entrepreneur-in-Residence at the University of California, San Francisco Innovation Ventures. Prior to Exai and UCSF, Pat was co-founder and CEO for Bluestar Genomics, CEO for Critical Diagnostics, and a member of the founding management teams at Tethys Bioscience (acquired by HDL) and Intersect ENT (acquired by Medtronic). Pat began his career as a financial advisor and strategy consultant in the private equity industry, entering the diagnostic field as the turnaround CEO for First Medical (acquired by Sigma-Aldrich). He has a master’s degree in management from the Stanford Graduate School of Business and a bachelors degree in molecular biology from Princeton University.


Clinical Dx Showcase:
Exai Bio Inc

Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, and treated in a personalized way. The company's propriety RNA and AI-based liquid biopsy platform delivers clinical insights into cancer biology.

Orphan Non-coding RNA (OncRNA): A Novel Liquid Biopsy Technology
Orphan non-coding RNAs (OncRNAs) are a novel technology platform, enabling a next-generation RNA-based liquid biopsy strategy.

 Speaker Profile

Ph.D., Sr. Scientific & Clinical Affairs Specialist , Novosanis

Biography
Jhana Hendrickx holds a master degree in bio-engineering, specializing in cell and gene biotechnology and applications for human health engineering, and a doctoral degree in biomedical sciences. Jhana joined Novosanis, a medical device company and subsidiary of OraSure Technologies Inc., in 2021. She’s in charge of scientific affairs, managing the Key Opinion Leader network, running Scientific Advisory Boards and engaging with our customers. Also, she is in charge of clinical affairs and runs the in-house clinical trials in infectious diseases and oncology and supports trials executed by lead Principal Investigators globally.


Clinical Dx Showcase:
Novosanis

Novosanis is a wholly owned subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology.

FIRST-VOID URINE AS A LIQUID BIOPSY FOR DISEASE MONITORING
First-void urine as a non-invasive liquid biopsy for disease monitoring and diagnostics.

 Speaker Profile

Hebrew U.

Biography
Nir is a Professor of Computer Science and of Life Sciences at the Hebrew University of Jerusalem. Prof. Friedman pioneered the use of probabilistic graphical models in reverse engineering of regulatory networks from high-throughput biological assays. In the last decade he shifted his focus to studying molecular mechanisms of transcription and chromatin by combination of novel high-throughput experiments and analysis. He examines these questions both in basic science context and in application to medical diagnosis and decision-making. Prof. Friedman has published more than 150 papers in peer-reviewed journals and conferences. He is the recipient of multiple awards, including the Michael Bruno Memorial Award (Yad Hanadiv), the Alexander von Humboldt Research Award, and three Advanced Researcher ERC grants. Prof. Friedman co-authored a widely used textbook on probabilistic graphical models.


Clinical Dx Showcase:
Hebrew U.

 Speaker Profile

M.D., Consultant Medical Oncologist, CanCertain Limited

Biography
Dr. Mithun Shah is a Consultant Medical Oncologist specialising in medical oncology and malignant haematology. Based in Ahmedabad (India), Dr. Mithun Shah works as a Consultant Medical Oncologist at Zydus Hospitals and Gujarat Research & Medical Institute.


Clinical Dx Showcase:
CanCertain Limited

CanCertain utilises advanced 3D cell culture techniques to recommend personalised cancer treatments. With a turnaround time of just 8 working days, the CanCertain personalised plan helps the patient begin the most effective cancer treatment quickly, thus increasing the chances of early recovery.

CanCertain: Clinical Experience in India
Dr Shah presents clinical utility of CanCertain in Patients with advanced stage cancer.

 Speaker Profile

Ph.D., Senior Director, Business Development, Biodesix, Inc.

Biography
Matthew Pink has over 12 years of experience in the pharma and diagnostics industries. He leads the biopharma services division at Biodesix, Inc. He previously served as Director of Business Development at CSL Behring followed by U.S. Director of Research External Innovation. Matthew has a B.S. in Biology from the University of Wisconsin-Madison and a Ph.D. in Neuroscience from the University of Colorado.


Clinical Dx Showcase:
Biodesix, Inc.

Biodesix, Inc. provides end-to-end diagnostic services for biopharma partners, including biomarker discovery, assay design and development, fit-for-purpose regulatory strategies, clinical trial testing, commercialization, and companion diagnostic capabilities. For biopharmaceutical therapeutics in development, we uncover novel insights about tumor biology and patient immune response.

Blood-based multi-omics to guide IO treatment strategy
A case study on how Biodesix utilizes genomics and proteomics to identify patients for immunotherapy.

 Speaker Profile

SVP, Diagnostics Business, Personalis

Biography
Chris Hall joined Personalis in October 2022 as Senior Vice President and Head, Diagnostics Business. As part of the executive leadership team, Hall drives the vision and strategy for commercializing the company’s diagnostic product offerings. Hall brings over 20 years of experience in general management and product development within the diagnostics industry, most recently as CEO of Naring Health, Inc. Previously, he served as President, COO, and Chief Commercial Officer at Veracyte, Inc., where he led the company’s commercial entry into endocrinology and pulmonology and scaled its operational groups. Hall also served as SVP and Chief Business Officer at Berkeley HeartLab, Inc. (part of Celera Corporation), where he helped a new product launch and restructured operations to improve profitability and streamline delivery of services. Hall holds a BA in political science and economics from DePauw University and an MBA from Harvard Business School.


Clinical Dx Showcase:
Personalis

Personalis is transforming the active management of cancer through more personalized testing. With industry-leading products combining tumor-and-normal profiling with proprietary algorithms, you can detect recurrence at the earliest timepoints, confidently select therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.

It’s Personal: The NeXT Generation of LBx
Personalis is redefining precision oncology through more personalized tumor-informed assays.

 Speaker Profile

Pharm.D., Ph.D., President and CEO, Micronoma

Biography
Sandrine Miller-Montgomery, Pharm.D., Ph.D, is the Co-founder, President and CEO of Micronoma, the first cancer-detection company utilizing signals from microbial nucleic acids, to empower clinicians to diagnose cancer at an early stage with minimally invasive, microbiome-driven liquid biopsy technology. Before co-founding Micronoma, she was executive director of UC San Diego’s Center for Microbiome Innovation (CMI), which she co-led with renowned microbiome researcher, Dr. Rob Knight. Sandrine established a world-class team focused on expanding industry and academic collaborations in the field of microbiome research that resulted in raising more than tens of millions of dollars of financial support through key partnerships toward application of this science to AI, diet and nutrition, aging, environment, human disease understanding and more. Sandrine has a talent for assembling efficient and successful teams around innovative products as shown by her work at Helixis, acquired by Illumina, and Mo Bio Labs acquired by QIAGEN.


Clinical Dx Showcase:
Micronoma

Micronoma is the first cancer-detection company utilizing minimally invasive, microbiome-driven liquid biopsy technology for early-stage cancer detection. Founded in 2019 by leaders in microbiome research, with results publication in major papers (Nature, Science, Cell...) the company is headquartered in San Diego, California.

Microbiome driven liquid biopsy for early stage cancer detection
Microbiome driven liquid biopsy is not a contamination artefact but a capture of a biological reality.

 Speaker Profile

Ph.D., Chief Technology Officer, Karius

Biography
Sivan Bercovici is the Chief Technology Officer at Karius, where he leads the computational and data efforts aimed at unlocking the clinical value in the microbiome data. Throughout his career, Sivan has developed novel machine-learning methods and analytical platforms that address broad challenges in genetics and the study of human disease. Prior to Karius, Sivan was a co-founder and Chief Technology Officer at Lifecode. He obtained his Ph.D. in Computer Science from Technion - Israel Institute of Technology and completed his postdoctoral research at Stanford University, as part of Stanford’s Artificial Intelligence Laboratory.


Clinical Dx Showcase:
Karius

Karius sees a world where infectious disease is no longer a major threat to human health. With the Karius Test®, we deliver unprecedented diagnostic insight to enable physicians to make rapid treatment decisions.

Liquid biopsy into the microbial world
Microbial cfDNA: Novel chemistries, data, and ML provide unprecedented and unbiased access to unique microbial profiles.

 Speaker Profile

M.D., Ph.D., M.D., Ph.D., VP of Translational Medicine, Biofluidica

Biography
With over twenty years of experience in oncology, liquid biopsy, and molecular diagnostics, Dr. Wang will bring his expertise in clinical research, product development, and management to BioFluidica in 2022. As Vice President of Translational Medicine at BioFluidica, he drives and manages disease initiatives and clinical applications. Before joining BioFluidica, Dr. Wang served as the Vice President of Informatics at Mindera Health, Senior Director of Translational Research at Epic Sciences, and Director of Bioinformatics at AltheaDx, where he led the development of multiple clinical tests, genomics analysis pipelines, and machine learning algorithms. Mr. Wang has over 60 peerreviewed publications in journals, including sciences, PNAS, Blood and Cancer Research, etc. He earned an M.D. and Ph.D. from Jilin University and a certificate in business management.


Clinical Dx Showcase:
Biofluidica

BioFluidica innovates technology and processes to overcome the technical challenges that hinder the clinical application of liquid biopsy. BioFluidica created LiquidScan™ as an automated system for isolating and enriching circulating rare cells and exosomes from liquid biopsy samples and developed clinical molecular tests.

Accelerating Development of Liquid Biopsy Clinical Applications
LiquidScan, a rare cell and exosome enrichment system, has been adopted for various clinical applications.

 Speaker Profile

Ph.D., Chief Executive Officer, Member of the Board of Directors and Co-Founder , ARTIDIS, AG

Biography
Marija Plodinec co-founded ARTIDIS AG and in November 2017 became the CEO and a Member of the Board of Directors. She studied physics in Zagreb and received her doctorate in 2010 from the University of Basel. For twelve years, she has driven the development of ARTIDIS, a medical device for fast and early diagnosis of breast cancer based on a unique nanomechanical biomarker, bringing the technology from basic research to the first clinical studies. Marija Plodinec is a recognized expert in the field of physical sciences in oncology and has co-authored important scientific papers and patents in this field. She is also a member of several international organizations focusing on cancer research and its clinical applications. Under her leadership, ARTIDIS fundraised more than 35M USD, successfully completed the large clinical study on 545 patients in Switzerland, grew to +45 FTE and partnered up with leading US pharmaceutical and clinical institutions.


Clinical Dx Showcase:
ARTIDIS, AG

ARTIDIS AG is a clinical stage medical technology company developing the first nanotechnology platform for tissue analysis combined with a digital data platform intended for broad use in drug discovery, tissue engineering as well as for rapid diagnostics and personalized treatment optimization.

ARTIDIS: Changing the paradigm of tissue analysis.
ARTIDIS: Changing the paradigm of tissue analysis and delivering personalized patient treatment strategies with nanotechnology.

 Speaker Profile

Ph.D., Co-founder & CSO, Okomera

Biography
Sandra Jernström holds a PhD in cancer genetics from the University of Oslo, where she together with her colleagues integrated different omics data from a breast cancer cohort to better stratify the patients. She has expertise in high-throughput drug and siRNA screening of 2D and 3D cell culture models, where she explored the difference in drug resistance mechanisms seen between the culture models. Before joining Okomera, she worked as a postdoc at Karolinska Institute in Sweden, with the aim to develop a method to perform drug screening directly on patient biopsies in 3D, to be able to guide the treatment. For this project she won a significant research grant competition at the SLUSH conference in Finland in 2018. In 2020, she joined Okomera, where she leads the bio application team and is in charge of clinical partnerships to gain clinical validation of the technology.


Clinical Dx Showcase:
Okomera

Okomera has developed a technology for screening cancer biopsies in order to select the best treatment for each patient.

Precision Cancer Medicine on a chip
Functional screening for drug efficacy assessment using 3D microtumors derived from cancer biopsies.

 Speaker Profile

CEO, AccuraGen

Biography
George Cardoza joined AccuraGen following a 12+ year tenure at NeoGenomics Laboratories where he served as Chief Financial Officer (CFO) from 20092018; President, Pharma Services Division from 20182021; and as President and Chief Operating Officer (COO), Lab Operations from 20212022. Earlier in his career Cardoza served as CFO at Protocol Integrated Direct Marketing and several positions at Quest Diagnostics including Controller, Central Region. George earned his Bachelors Degree in Finance and Accounting from Syracuse University and his M.B.A. in Management from Michigan State University Eli Broad College of Business.


Clinical Dx Showcase:
AccuraGen

AccuraGen aims to revolutionize cancer management through technology innovation in molecular testing. AccuraGen focuses on the analysis of highly fragmented circulating nucleic acid in blood and has developed proprietary technologies enabling superior performance in the analysis of genomic, epigenetic, and RNA changes.

Company Introduction and Leading Liquid Biopsy Platform.
A unique liquid biopsy platform that offers best-in-class early cancer detection solution.

 Speaker Profile

Ph.D., CEO/Co-Founder, Resistance Bio

Biography
Dr. Goldner is a molecular biologist and entrepreneur focused on harnessing evolution to understand the longterm consequences of therapeutic intervention to improve patient outcomes.


Clinical Dx Showcase:
Resistance Bio

resistanceBio has developed a novel method and algorithm for picking up resistance mechanisms that current technologies cannot identify. We utilize a proprietary tissue culture technology termed the ResCu system to more accurately recapitulate the emergence of resistance seen in the clinic.

Capturing Cancers Adaptive Resistance Profiles Via the ResSu Syst
resistanceBio has developed a novel method and algorithm for picking up resistance mechanisms.

 Speaker Profile

Ph.D., PHARMD, CEO, Presagen

Biography
Dr. Michelle Perugini is an academic and health tech entrepreneur with extensive experience in healthcare and advanced AI technologies. Michelle is also a dedicated advisor to many start-ups, a member of numerous Government Committees, and an avid supporter of the AI and women’s health sectors globally. She has a PhD in Medicine and was a post-doctoral research fellow in Oncology for a decade. She has founded 2 global AI tech companies, the first of which was acquired by EY in 2015. Michelle is currently Co-Founder and CEO of Presagen, an AI healthcare company building The Social Network for Healthcare, with a focus in women’s health. Presagen’s first product Life Whisperer uses AI for embryo selection to improve pregnancy outcomes in IVF, and is being sold in IVF clinics globally.

Talk

AI often lacks scalability as it is based on biased data that lacks diversity. Presagen's Social Network model enables global collaboration and data sharing by clinics and patients, creating AI healthcare products that are globally scalable, accessible and affordable for all.


Clinical Dx Showcase
Presagen: The Social Network for Healthcare